Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...

Immvention Therapeutix is partnering with Novo Nordisk to develop oral treatments for sickle cell disease (SCD) and other ...

IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...

New data from a Phase 1b clinical trial testing Fulcrum's pociredir for sickle cell disease are expected by the middle and ...

BEAM-101 demonstrated robust and durable increases in fetal hemoglobin and reductions in sickle hemoglobin, showcasing its potential effectiveness in treating sickle cell disease. The safety ...

IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...

Adults with sickle cell anemia (SCA) and healthy controls with greater economic deprivation have older brain age, acco ...

Currently in preclinical development, IMMvention’s orally dosed BACH1 inhibitors have the potential to increase fetal hemoglobin ... address unmet needs in sickle cell disease and beyond ...

Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will encore data from the BEACON Phase 1/2 ...

IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...

Treatment with BEAM-101 demonstrated robust and durable increases in fetal hemoglobin (HbF ... genetically modified cell therapy for the treatment of severe sickle cell disease (SCD).